MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/jim-2020-001525

Медицинская библиотека · Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2021

ALLY in fighting COVID-19: magnitude of albumin decline and lymphopenia (ALLY) predict progression to critical disease.

van Zyl Johanna S, Alam Amit, Felius Joost, Youssef Ronnie M, Bhakta Dipesh, Jack Christina, Jamil Aayla K, Hall Shelley A, Klintmalm Göran B, Spak Cedric W, Gottlieb Robert L

СтатьяВалидационное исследованиеПеревод пока не подготовлен

Аннотация

The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic leading to coronavirus disease 2019 (COVID-19) is straining hospitals. Judicious resource allocation is paramount but difficult due to the unpredictable disease course. Once hospitalized, discerning which patients may progress to critical disease would be valuable for resource planning. Medical records were reviewed for consecutive hospitalized patients with COVID-19 in a large healthcare system in Texas. The main outcome was progression to critical disease within 10 days from admission. Albumin trends from admission to 7 days were analyzed using mixed-effects models, and progression to critical disease was modeled by multivariable logistic regression of laboratory results. Risk models were evaluated in an independent group. Of 153 non-critical patients, 28 (18%) progressed to critical disease. The rate of decrease in mean baseline-corrected (Δ) albumin was -0.08 g/dL/day (95% CI -0.11 to -0.04; p<0.001) or four times faster, in those who progressed compared with those who did not progress. A model of Δ albumin combined with lymphocyte percentage predicting progression to critical disease was validated in 60 separate patients (sensitivity, 0.70; specificity, 0.74). ALLY (delta albumin and lymphocyte percentage) is a simple tool to identify patients with COVID-19 at higher risk of disease progression when: (1) a 0.9 g/dL or greater albumin drop from baseline within 5 days of admission or (2) baseline lymphocyte of ≤10% is observed. The ALLY tool identified >70% of hospitalized cases that progressed to critical COVID-19 disease. We recommend prospectively tracking albumin. This is a globally applicable tool for all healthcare systems.

Для цитирования: van Zyl Johanna S, Alam Amit, Felius Joost, Youssef Ronnie M, Bhakta Dipesh, Jack Christina, Jamil Aayla K, Hall Shelley A, Klintmalm Göran B, Spak Cedric W, Gottlieb Robert L. ALLY in fighting COVID-19: magnitude of albumin decline and lymphopenia (ALLY) predict progression to critical disease.. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2021. DOI: 10.1136/jim-2020-001525.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.